Cholecystokinin is a regulator of intestinal phase-stimulated PP release.
The purpose of this study was to determine the role of CCK during the intestinal phase of pancreatic polypeptide (PP) release in man. We first compared the PP response to exogenous caerulein infusion in the presence or absence of either loxiglumide (a specific CCK antagonist) or atropine in six healthy subjects. In the second part of the study, a meal was perfused to the duodenum with and without either loxiglumide or atropine. Both loxiglumide and atropine completely abolished the PP response to exogenous or endogenous stimulation (P less than 0.05). We conclude that CCK participates in the intestinal phase of PP secretion.
Adler
G
G
Department of Internal Medicine, Phillips University, Marburg, F.R.G.
Beglinger
C
C
Braun
U
U
Reinshagen
M
M
Koop
I
I
Schafmayer
A
A
D000328:Adult; D001285:Atropine / Q000494:pharmacology; D002108:Ceruletide / Q000008:administration & dosage; D002766:Cholecystokinin / Q000037:antagonists & inhibitors / Q000502:physiology*; D006801:Humans; D007262:Infusions, Intravenous; D007413:Intestinal Mucosa / Q000378:metabolism*; D008297:Male; D010191:Pancreatic Polypeptide / Q000378:metabolism*; D011377:Proglumide / Q000031:analogs & derivatives / Q000494:pharmacology
D010191:Pancreatic Polypeptide; C053737:loxiglumide; D001285:Atropine; D002108:Ceruletide; D002766:Cholecystokinin; D011377:Proglumide